Navigation Links
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Date:9/25/2007

BARCELONA, Spain, Sept. 25 /PRNewswire/ -- Five-year follow-up overall survival data from the X-ACT (Xeloda in Adjuvant Colon Cancer Trial) study show that oral chemotherapy Xeloda(R) (capecitabine) is as effective as the current standard treatment - intravenous bolus 5-FU/LV (5-fluorouracil/ leucovorin) - in the adjuvant treatment of Dukes' C colon cancer. These data were presented today at the 14th European Cancer Conference (ECCO) in Barcelona, Spain.

Results show five-year overall survival rates for Xeloda at 71.4 percent compared to 68.4 percent in the 5-FU/LV arm. Additional data presented at the meeting from a previous analysis show that Xeloda is also comparable to 5- FU/LV with respect to disease-free survival (DFS) and relapse-free survival (RFS).

"These updated five-year overall survival data provide further proof that Xeloda can be a safe and effective alternative to the current standard of care for adjuvant colorectal cancer, which can require upwards of 30 clinic visits over the 24-week treatment course," said Dr. Howard Burris of the Sarah Cannon Research Institute, Nashville, Tenn., and lead U.S. investigator in the study. "Based on this evidence, physicians - especially those who have relied on 5- FU/LV - should feel confident about exploring Xeloda as a treatment option with their patients who could benefit from the flexibility of oral chemotherapy."

Previous results from the X-ACT study also show that Xeloda is more cost- effective than the Mayo Clinic regimen (the current standard treatment) and is associated with fewer side effects. Additionally, many of the side effects can be easily managed by altering the dose without compromising efficacy.(1,2) In the same analysis, costs for medicines to treat side effects, such as nausea and diarrhea, were cut by nearly 75 percent in the Xeloda arm compared to use of intravenous 5-FU/LV.

"We are pleased to see that Xeloda is standing up to its initial promise as an alternativ
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... and ZURICH , May 17, ... Agency for Science, Technology and Research (A*STAR) and ... first healthy volunteer has been dosed in a Phase 1 ... Cytos, proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In this ... this novel vaccine candidate and its potential to protect against ...
(Date:5/16/2013)... SAN FRANCISCO , May 16, 2013  Nektar Therapeutics, ... Howard W. Robin , is scheduled to ... New York at the Sheraton New ... Eastern time. The presentation will be accessible via ... Events Calendar section of the Nektar website: http://www.nektar.com . ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... take charge of their health at home through the merger ... dividend of $3.00 per share on its Series B Convertible ... July 15, 2013 to holders of record of Series B ... Such payment will cover the amount of all ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... Acorda,Therapeutics (Nasdaq: ACOR) today announced that Andrew Goodman,M.D., ... University,of Rochester, will present data from Acorda's MS-F203 ... at the,upcoming American Academy of Neurology (AAN) meeting. ... 2, 2007 at 4:15 pm,Eastern Time (ET). This ...
... Mice Show Reduction of Enzyme Substrate, CRANBURY, ... a biopharmaceutical company developing,small-molecule, orally administered pharmacological ... announced today that the,Company will present results ... compound in development for the,treatment of Fabry ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 2Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease 3
(Date:5/19/2013)... Aires, Argentina: Yoga classes ( clases de Yoga ) ... the Sivananda Yoga Vedanta Center. The center is ... Classes are 90 minutes and are offered all week ... calm environment, allowing visitors to enjoy the benefits of ... others. , The Yoga classes follow the following principles: ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
(Date:5/18/2013)... Daily Gossip issued a press release last week to announce ... Colston, Daily Gossip’s spokesperson, told the press that the magazine ... Fat Loss Plan . , Shaun Hadsall was the ... time when nutritionists and fat loss gurus constantly told people ... diet is based on the Macro-Patterning scheme, according ...
(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...
(Date:5/18/2013)... News) -- Children who swallow high-powered magnets often need ... according to a new study. The researchers, from ... found that more than 79 percent of children who ... an endoscopic procedure, in which a tube containing a ... percent of these cases can be treated through observation ...
Breaking Medicine News(10 mins):Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2
... Efficiency, SAN RAMON, Calif., May 29 ... specializes in enabling,transformation of its clients, business and ... $1.5 million five-year contract with Golden Living, a,network ... nursing,facilities and 19 assisted living facilities in 22 ...
... Ill.--The interaction of sex, age and ethnicity has a ... (MCRC) patients, a study led by researchers at the ... Center suggests. , While age and ethnicity ... the study found that gender also plays an important ...
... Patients suffering from hemineglect cannot attend to, and hence ... sometimes these ignored stimuli may be processed without awareness. ... of Cortex, Jerome Sackur and colleagues at Unit de ... hemineglect is not limited to low level features of ...
... Be Part of the Festivities, NEW YORK, May 29 ... Drug-Free America(R) and MetLife Foundation,found that parents, personal past experiences ... the rules and limits they set for,their teens during this ... who drank or used drugs at their own,proms or graduations ...
... of studies features biomechanical analysis of footwear, INDIANAPOLIS, ... footwear option during warm summer months may,experience lower leg ... presented today at the 55th Annual Meeting of the ... are very common, and this study began with the ...
... 29 DigitalRodeo.com has announced,today that they have coordinated ... on Saturday, May 31st at Hotel Indigo, on,West End, ... country music community that offers a,place for you to ... have an,unlimited opportunity to discover the world of country ...
Cached Medicine News:Health News:Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company 2Health News:Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company 3Health News:USC study finds sex, age and ethnicity assciated with colorectal cancer survival 2Health News:Survey: Parents Let Their Own Experiences Affect Drug and Alcohol Boundaries Set for Teens at Prom and Graduation Parties 2Health News:Survey: Parents Let Their Own Experiences Affect Drug and Alcohol Boundaries Set for Teens at Prom and Graduation Parties 3Health News:Survey: Parents Let Their Own Experiences Affect Drug and Alcohol Boundaries Set for Teens at Prom and Graduation Parties 4Health News:Survey: Parents Let Their Own Experiences Affect Drug and Alcohol Boundaries Set for Teens at Prom and Graduation Parties 5Health News:Flip-Flops, Heels Examined for Performance, Impact 2Health News:Flip-Flops, Heels Examined for Performance, Impact 3Health News:DigitalRodeo.com Lines Up Entertainment for Rhinestone Cure 2
Using the patient's own blood pressure as the driving force, CAVR circulates cold blood through the Level 1 heat exchanger and returns it to the patient at body temperature for rapid core rewarming....
... HOTLINE can deliver normothermic fluid to your ... HOTLINE tubing design surrounds the patient line ... eliminating patient line cool down. The HOTLINE ... position, requires less priming volume, and is ...
... control panel is conveniently located on the swivel ... whether standing or sitting. The ventilator control panel ... numerics. The ventilator has CMV, PCV and SIME ... in two lengths facilitates both the placing of ...
... provides high quality ventilation and monitoring ... technologies of the AV2+ ventilator, breathing ... GS user-friendly and intuitive. , ... GS is the perfect introduction to ...
Medicine Products: